Review paper
AODTH-003 Vedolizumab clinical and post-marketing safety experience of opportunistic infections
Published: Jun 17, 2017
Abstract
Introduction
The risk of opportunistic infections (OIs) in inflammatory bowel disease increases with the use of biologics compared with placebo (odds ratio [OR]: 1.90).1 Vedolizumab (VDZ), a humanised monoclonal antibody, targets α4β7 integrin and selectively blocks gut-specific lymphocyte trafficking. Gut selectivity may be associated with a lower risk of infection compared with anti-tumour necrosis...Paper Details
Title
AODTH-003 Vedolizumab clinical and post-marketing safety experience of opportunistic infections
Published Date
Jun 17, 2017
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History